You just read:

Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses

News provided by

Inovio Pharmaceuticals, Inc.

Sep 14, 2011, 04:00 ET